Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

OBJECTIVE: To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan. BACKGROUND: Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan. To the best of our knowledge, no real-world studies on galcanez...

Descripción completa

Detalles Bibliográficos
Autores principales: Takizawa, Tsubasa, Ohtani, Seiya, Watanabe, Narumi, Miyazaki, Naoki, Ishizuchi, Kei, Sekiguchi, Koji, Iba, Chisato, Shibata, Mamoru, Takemura, Ryo, Hori, Satoko, Nakahara, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805082/
https://www.ncbi.nlm.nih.gov/pubmed/36585619
http://dx.doi.org/10.1186/s12883-022-03041-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805082/
https://www.ncbi.nlm.nih.gov/pubmed/36585619
http://dx.doi.org/10.1186/s12883-022-03041-1

Ejemplares similares